- Conditions
- Mild Cognitive Impairment and Dementia
- Interventions
- Not listed
- Lead sponsor
- Koser, Robert B., MD PA
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Bradenton, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–21
of 21
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer's Disease
- Interventions
- No Intervention
- Other
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 6,700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 1
- States / cities
- Nutley, New Jersey
- Conditions
- Alzheimer Disease
- Interventions
- Rivastigmine 5 cm^2, Rivastigmine 10 cm^2, Rivastigmine 15 cm^2, Placebo to 15 cm^2 patch, Placebo to 10 cm^2 patch
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 1,584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more
- Conditions
- Alzheimer´s Disease
- Interventions
- Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
- Drug
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 51 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Aerobic Exercise
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease 4, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 7, Alzheimer Disease 8, Alzheimer Disease 9, Late-Onset, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 17, Alzheimer Disease 18, Alzheimer Disease 19, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease Focal
- Interventions
- No Intervention
- Other
- Lead sponsor
- ProgenaBiome
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Ventura, California
- Conditions
- Mild Cognitive Impairment
- Interventions
- NewGam 10% IVIG, Placebo
- Drug · Other
- Lead sponsor
- Sutter Health
- Other
- Eligibility
- 50 Years to 84 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Alzheimer's Disease
- Interventions
- Donepezil TDS
- Drug
- Lead sponsor
- Corium, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Alzheimer Disease
- Interventions
- PF-04494700 - Low Dose Arm, PF-04494700 - High Dose Arm, Placebo Comparator
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 12
- States / cities
- Sun City, Arizona • Fresno, California • San Diego, California + 9 more
- Conditions
- Alzheimer´s Disease
- Interventions
- Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg, Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg, Placebo solution: Human Albumin 0.25% - 4 mL/kg, Placebo solution: Human Albumin 0.25% - 2 mL/kg
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 34 more
- Conditions
- Alzheimer Disease
- Interventions
- florbetapir F 18
- Drug
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 3
- States / cities
- West Palm Beach, Florida • North East, Maryland • Clementon, New Jersey
- Conditions
- Alzheimer's Disease
- Interventions
- Placebo, octagam 10%
- Drug · Biological
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Hoboken, New Jersey
- Conditions
- Alzheimer´s Disease
- Interventions
- Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 34 more
- Conditions
- Dementia, Alzheimer's Disease
- Interventions
- Rasagiline
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 31
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 24 more
- Conditions
- Alzheimer's Disease
- Interventions
- Rivastigmine, memantine
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Paterson, New Jersey
- Conditions
- Alzheimer Disease
- Interventions
- AVE1625
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Alzheimer's Disease
- Interventions
- Aricept (donepezil SR 23 mg), Aricept (donepezil IR 10 mg)
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 1,467 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Hickory, North Carolina
- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
- Interventions
- Spectris™ AD - Active, Spectris™ AD - Sham
- Device
- Lead sponsor
- Cognito Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 673 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 68
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more
- Conditions
- Alzheimer's Disease, Amnestic Mild Cognitive Impairment
- Interventions
- Posiphen® tartrate capsules
- Drug
- Lead sponsor
- Annovis Bio Inc.
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Dementia Moderate, Dementia, Mild, Alzheimer Disease
- Interventions
- Xanamem, Placebo
- Drug
- Lead sponsor
- Actinogen Medical
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 19
- States / cities
- Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more
- Conditions
- Depressive Symptoms
- Interventions
- Acceptance and commitment therapy (ACT), Psychoeducation
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama